Skip to content

Author

Filipe Moura

We have 2 of 34 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Comparative risk assessment of cardiovascular and kidney outcomes in patients with type 2 diabetes using cystatin C and creatinine in DECLARE-TIMI 58

Background The relationship between cystatin C and cardiovascular and kidney outcomes is not well explored in individuals with type 2 diabetes (T2D) and normal or mild kidney dysfunction. Methods This nested prospective biomarker study included patients enrolled in DECLARE-TIMI 58. Participants were categorized into qu...

Andre M. Small, David D. Berg, Itamar Raz et al. · 0 citations
Aug 2026

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

Annabel Z. Wang, V. Alexander, T. Prohaska et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.